Skip to main content

Nivolumab represents ‘new treatment option’ for advanced gastric cancer

Nivolumab significantly prolongs survival, versus placebo, in heavily pretreated patients with unresectable gastric or gastro-esophageal junction cancer, ATTRACTION-2 study findings indicate.
Narikazu Boku (National Cancer Center Hospital, Tokyo, Japan) and co-researchers say their results suggest that nivolumab “might be a new treatment option” for these patients, who currently have no standard of care therapy available and typically have poor prognosis.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino